Vincent John
Pfizer Inc., New York, New York, USA.
Clin Pharmacol Ther. 2017 Sep;102(3):368-372. doi: 10.1002/cpt.775.
The focus of this edition of Clinical Pharmacolgoy & Therapeutics (CPT) is on drugs and renal function and will not include a detailed discussion of kidney disease and its treatment. It is well recognized that drugs affect the kidneys in different ways, while kidney disease impacts drug metabolism and response. It is impossible to underestimate the value of the kidneys to man in health and disease, from regulation of fluid and electrolyte balance to participating in drug metabolism and transport. Additionally, the kidneys serve as targets for drugs used to treat cardiovascular (CV) diseases including hypertension and heart failure, metabolic diseases such as diabetes mellitus and obesity, chronic kidney disease (CKD), as well as playing a role in the regulation of several hormones. Kidney damage may be distinguished from changes in kidney function using biomarkers, as discussed in some detail in this issue.
本期《临床药理学与治疗学》（CPT）的重点是药物与肾功能，不包括对肾脏疾病及其治疗的详细讨论。众所周知，药物以不同方式影响肾脏，而肾脏疾病会影响药物代谢和反应。肾脏对人类健康和疾病的价值不可低估，从调节体液和电解质平衡到参与药物代谢和转运。此外，肾脏是用于治疗心血管（CV）疾病（包括高血压和心力衰竭）、代谢疾病（如糖尿病和肥胖症）、慢性肾脏病（CKD）的药物靶点，并且在多种激素的调节中发挥作用。如本期详细讨论的，可使用生物标志物区分肾损伤与肾功能变化。
